![Silverback Therapeutics](https://gocience.com/logos/new/b6acebef58396d867c95f1cd3467a40e83e54c6b61163f954b7decc650ad3507.jpg)
Silverback Therapeutics
Biotechnology, El Camino Real, Seattle, , 92130, Washington, 11682, United States, 51-200 Employees
Who is SILVERBACK THERAPEUTICS
We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatmen...
Read More
![map](/x-assets/maps1.0-950f22e3512fa69a51fdf6612dcb593a74c2f8790b6e4ec5601cebb82b592ab9.png)
-
Headquarters: 11682 El Camino Real, Seattle, Washington, 92130, United States
-
Date Founded: 2016
-
Employees: 51-200
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 561110 |
Show More
Does something look wrong? Fix it. | View contact records from SILVERBACK THERAPEUTICS
Silverback Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Silverback Therapeutics
Answer: Silverback Therapeutics's headquarters are located at El Camino Real, Seattle, , 92130, Washington, 11682, United States
Answer: Silverback Therapeutics's official website is https://silverbacktx.com
Answer: Silverback Therapeutics's revenue is $25 Million to $50 Million
Answer: Silverback Therapeutics's SIC: 2834
Answer: Silverback Therapeutics's NAICS: 561110
Answer: Silverback Therapeutics has 51-200 employees
Answer: Silverback Therapeutics is in Biotechnology
Answer: Silverback Therapeutics contact info: Phone number: Website: https://silverbacktx.com
Answer: We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are creating a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month